Third quarter 2022 total revenue of $90.7 million and Crysvita® revenue in Ultragenyx territories1 of $64.5 million
Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million
Enrollment completion of DTX401 Phase 3, UX143 Phase 2, and GTX-102 dose escalation cohorts anticipated around the end of the year
https://finance.yahoo.com/news/ultragenyx-reports-third-quarter-2022-200500018.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.